Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ====== 1993 ====== [[1992]]-[[1994]] ---- Brantigan and Steffee ((Brantigan JW, Steffee AD. A [[carbon fiber]] implant to aid [[interbody]] [[lumbar fusion]]. Two-year clinical results in the first 26 patients. Spine (Phila Pa 1976) 1993;18:2106–7. )) combined [[interbody fusion]] with [[pedicle screw]]/[[plate]] [[stabilization]] of the [[lumbar spine]] in [[1993]]. ---- ---- In [[1993]] [[Engelbert Knosp]] et al. offered the [[Knosp grade]] system for showing invasion of [[cavernous sinus]] by [[pituitary macroadenoma]]. Briefly, the much laterally adenoma grows and surrounds the [[internal carotid artery]] (ICA), the more grade level is. The grading defined by the relation of carotid lines with the limits of invasion. These lines passes through supra- and [[intracavernous internal carotid artery]] in [[coronal]] view. There are medial, median and lateral carotid lines ((Knosp E, Steiner E, Kitz K, Matula C. pituitary neuroendocrine tumors with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8. PubMed PMID: 8232800. )). ---- The first edition of the [[World Health Organization Classification of Tumors of the Central Nervous System]] was published in [[1979]] and took almost a decade to complete. The second edition followed in [[1993]] and was considered a great step forward as it incorporated the advances in classification resulting from the introduction of [[immunohistochemistry]]. ---- In [[1993]], Mayer and Brock reported the use of tubular retractors. Foley and Smith performed a video-assisted technique using a tubular work canal (Micro-endoscopic discectomy: MED) via a 2-cm incision adopting a trans-muscular approach without multifidus release from its insertion in [[1997]]. ---- ---- Biallelic inactivation of the NF2 gene has been established as the principal underlying genetic event in patients with sporadic and syndrome-associated vestibular schwannoma (VS). Two independent teams contemporaneously identified the NF2 gene located on [[chromosome 22]] at 22q12.2 in [[1993]], which codes for the tumor suppressor protein Merlin, also called schwannomin The NF2 gene provides instructions for the production of a protein called [[merlin]], also known as [[schwannomin]] ((Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515–21.)) ((Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791–800.)). 1993.txt Last modified: 2024/06/07 02:54by 127.0.0.1